SINT vs. DRIO, PYPD, FEMY, ALUR, NEPH, RVP, OSRH, QTI, CLGN, and NXGL
Should you be buying Sintx Technologies stock or one of its competitors? The main competitors of Sintx Technologies include DarioHealth (DRIO), PolyPid (PYPD), Femasys (FEMY), Allurion Technologies (ALUR), Nephros (NEPH), Retractable Technologies (RVP), OSR (OSRH), QT Imaging (QTI), CollPlant Biotechnologies (CLGN), and NEXGEL (NXGL). These companies are all part of the "medical equipment" industry.
Sintx Technologies vs.
Sintx Technologies (NASDAQ:SINT) and DarioHealth (NASDAQ:DRIO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, risk, dividends, valuation, media sentiment, analyst recommendations, earnings, institutional ownership and community ranking.
Sintx Technologies currently has a consensus target price of $30.00, suggesting a potential upside of 886.84%. DarioHealth has a consensus target price of $2.00, suggesting a potential upside of 189.81%. Given Sintx Technologies' stronger consensus rating and higher probable upside, analysts clearly believe Sintx Technologies is more favorable than DarioHealth.
Sintx Technologies has higher earnings, but lower revenue than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Sintx Technologies, indicating that it is currently the more affordable of the two stocks.
In the previous week, Sintx Technologies and Sintx Technologies both had 6 articles in the media. Sintx Technologies' average media sentiment score of -0.01 beat DarioHealth's score of -0.30 indicating that Sintx Technologies is being referred to more favorably in the media.
DarioHealth has a net margin of -205.62% compared to Sintx Technologies' net margin of -358.79%. DarioHealth's return on equity of -72.16% beat Sintx Technologies' return on equity.
Sintx Technologies has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
18.4% of Sintx Technologies shares are held by institutional investors. Comparatively, 33.4% of DarioHealth shares are held by institutional investors. 0.0% of Sintx Technologies shares are held by company insiders. Comparatively, 10.9% of DarioHealth shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
DarioHealth received 203 more outperform votes than Sintx Technologies when rated by MarketBeat users. Likewise, 67.04% of users gave DarioHealth an outperform vote while only 61.67% of users gave Sintx Technologies an outperform vote.
Summary
DarioHealth beats Sintx Technologies on 11 of the 17 factors compared between the two stocks.
Get Sintx Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for SINT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Sintx Technologies Competitors List
Related Companies and Tools
This page (NASDAQ:SINT) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy SINT Stock Free SINT Stock Alerts